Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects

Determinants of conditioned reinforcing effectiveness: Dopamine D2-like receptor agonist-stimulated responding for cocaine-associated stimuli

(2015) Gregory T. Collins et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Activation of a ventral hippocampus–medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine

(2015) F R Carreno et al.   MOLECULAR PSYCHIATRY

Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors

(2015) Jonathan Fischell et al.   NEUROPSYCHOPHARMACOLOGY

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

(2014) Gerard Sanacora et al.   NEUROPSYCHOPHARMACOLOGY

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice

(2011) J Braudeau et al.   JOURNAL OF PSYCHOPHARMACOLOGY

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

(2011) Anita E. Autry et al.   NATURE

The predictive validity of the rat self-administration model for abuse liability

(2010) Eoin C. O’Connor et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS